Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Lymphocytes of animals with delayed hypersensitivity produce mediators of cellular immunity when challenged in vitro with specific antigen. Among these are macrophage migration inhibitory factor (MIF) and interferon (IF). Nonspecific mitogens also induce the production of these lymphokines. In the following study leukocytes and column-purified lymphocytes of the same peripheral blood sample from tuberculin (purified protein derivatives [PPD])-sensitive rabbits were concurrently cultured in medium alone or with PPD. Supernatants of 1- and 4-day lymphocyte cultures were assayed for MIF. Supernatants of 1-, 2- to 4- and 5- to 7-day leukocyte cultures were assayed for IF by inhibition of cytopathic effect of vesicular stomatitis virus on rabbit kidney cultures. In the presence of PPD, normal lymphocytes did not produce MIF, but lymphocytes from sensitized animals did (8/8 animals), after 1 and 4 days of culture. Leukocytes from normal animals produced little or no IF when cultured with or without PPD. Leukocytes from sensitized animals cultured in medium alone produced little IF. However, when cultured with PPD they produced significant amounts of IF on day-1 (6/8 animals) and day-2 to day-4 (4/8) animals. There was no correlation between relative amounts of MIF and IF produced by cultures of respective cells from individual animals. Rabbit IF produced or released in vitro appeared in significant and maximum amounts by 24 h coincident with the time release of significant amounts of another mediator of cellular immunity, MIF.
 ...
PMID:Immunologically specific production of interferon in cultures of rabbit blood lymphocytes: association with in vitro tests for cell-mediated immunity. 5 4

Variability in the efficacies and toxicities of anticancer agents is a major problem. We hypothesized that polymorphisms in cytokine gene promoters may underlie genetic susceptibility to chemotherapy-induced toxicities in the Japanese. DNA was extracted from 100 patients undergoing 5-fluorouracil plus cisplatin chemotherapy. We used a case-only design to evaluate the relation between toxicities and cytokine promoter gene polymorphisms. The following polymorphisms were genotyped: tumor necrosis factor (TNF)-alpha-1031T/C, interleukin (IL)-1beta-511C/T, IL-6-634C/G, IL-10-819T/C, IL-18-137G/C, macrophage migration inhibitory factor -173G/C, and 86-basepair variable numbers of tandem repeat in intron 2 of the IL-1 receptor antagonist. The frequency of the IL-6-634 GC and GG genotypes was significantly higher in patients with grades 1-4 leukopenia (P=0.003; Crude-odds ratios (Cr-OR) =4.0), neutropenia (P=0.0051; Cr-OR=3.6), or thrombocytopenia (P<0.0001; Cr-OR=6.1) than in patients without these toxicities. Similarly, the frequency of the IL-1beta-511 TC and TT genotypes and the frequency of the TNF-alpha-1031 TT genotype were significantly higher in patients with grades 1-4 thrombocytopenia (P=0.015; Cr-OR=2.9) and stomatitis (P=0.02; Cr-OR=3.1), respectively. Multivariate analysis of factors such as age, sex, disease type, purpose of the chemotherapy, use of radiotherapy, and cytokine promoter gene polymorphisms showed polymorphisms to be significant predictors of toxicity. Our results suggest that polymorphisms in cytokine gene promoters may be associated with susceptibilities to leukopenia, neutropenia, thrombocytopenia and stomatitis in patients treated with 5-fluorouracil plus cisplatin.
 ...
PMID:Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy. 1682 Sep 19